Wosen Biologics: Plans to issue shares to specific entities, with subscription amounts not exceeding 2.203 billion yuan.

Watson Bio announced that the company plans to issue no more than 208 million A-shares to a specific entity, Tengyun Xinwo, with a subscription amount not exceeding 2.203 billion yuan, to supplement working capital. Upon completion of the issuance, Tengyun Xinwo will become the controlling shareholder, and Huang Tao will be the actual controller. The subscription shares will be subject to a lock-up period of 36 months. This issuance is still subject to approval from the company's shareholder meeting, the State Administration for Market Regulation, the Shenzhen Stock Exchange, the China Securities Regulatory Commission, and other authorities, and it is uncertain whether it will receive approval and the timeline for such approval.